Paper · 19665931

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.

Douw L and 14 others. Lancet Neurol, 2009. Cited by 576 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Papers, record 19665931. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19665931

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up.; PubMed
Journal: Lancet Neurol; PubMed
Year: 2009; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/19665931/; PubMed
DOI: https://doi.org/10.1016/s1474-4422(09)70204-2; PubMed
The journal: https://conductscience.org/library/journal-index/101139309; PubMed
Citations, by iCite: 576; iCite
Relative citation ratio, by iCite: 16.5; iCite
Revised in PubMed: 2022-04-09; PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Douw L	Linda
2	Klein M	Martin
3	Fagel SS	Selene Saa
4	van den Heuvel J	Josje
5	Taphoorn MJ	Martin Jb
6	Aaronson NK	Neil K
7	Postma TJ	Tjeerd J
8	Vandertop WP	W Peter
9	Mooij JJ	Jacob J
10	Boerman RH	Rudolf H

1 to 10 of 15Source PubMed

See all 15 authors

Topics22

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Brain	Major topic
Brain Neoplasms	Major topic
Cognition Disorders	Major topic
Glioma	Major topic
Radiotherapy	Major topic
Adult
Atrophy
Attention
Disease Progression
Female
Follow-Up Studies
Humans
Longitudinal Studies
Magnetic Resonance Imaging
Male
Memory Disorders
Middle Aged
Neuropsychological Tests
Radiation Dosage
Retrospective Studies
Risk Assessment
Time

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References0

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

None in this release.

Cited by353

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 576 citations.

PMID	Title	Journal	Year	In Papers	Source
42,877,165	A peri-tumoral TREM2-high myeloid state, myeloid continuum polarization, and white matter disconnection in long-term cognitive survivorship after diffuse glioma: a neuroimmune-connectomic cohort study.	Front Immunol	2026	https://conductscience.org/library/papers/42877165	PubMed
42,789,135	White matter pathlength maps from diffusion-weighted MRI tractography for radiotherapy target planning in glioblastoma.	J Neurooncol	2026	https://conductscience.org/library/papers/42789135	PubMed
42,750,913	Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase‑mutant glioma in 2026: Adapting clinical practice to the molecular era.	Neurooncol Pract	2026	https://conductscience.org/library/papers/42750913	PubMed
42,750,793	Contribution of cognitive function and fatigue to health-related quality of life in patients with IDH-mutant gliomas from diagnosis to long-term follow-up.	Neurooncol Pract	2026	https://conductscience.org/library/papers/42750793	PubMed
42,583,629	Modeling tumor volume trajectory and outcome identifies 3 distinct response classes in lower-grade IDH-mutant glioma receiving first-line chemotherapy.	Neurooncol Adv	2026	https://conductscience.org/library/papers/42583629	PubMed
42,474,656	Regulatory delay and lost opportunity in IDH-mutant low-grade glioma.	Clin Transl Oncol	2026	https://conductscience.org/library/papers/42474656	PubMed
42,449,655	Cognitive Functioning of Low-Grade Glioma Patients with and Without Adjuvant Treatment Before and One Year After Tumor Resection.	Cancers (Basel)	2026	https://conductscience.org/library/papers/42449655	PubMed
42,430,039	Current Treatment Options for Adult Grade 2 IDH-mutant Diffuse Gliomas in the Vorasidenib Era: Patient Selection, Sequencing, and Practical Management.	Curr Treat Options Oncol	2026	https://conductscience.org/library/papers/42430039	PubMed
42,338,700	Wide dural radiation therapy for NF2-SWN associated meningiomatosis.	Clin Transl Radiat Oncol	2026	https://conductscience.org/library/papers/42338700	PubMed
42,338,462	Cancer treatment-related cognitive impairment.	Neurooncol Adv	2026	https://conductscience.org/library/papers/42338462	PubMed

1 to 10 of 353

See all 353 cited by

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19665931

GET https://conductscience.org/api/papers/v1/19665931/cited_by?page=2

API reference For AI assistants